An optimized targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide variants

•NGS based detection of low-level SNVs is feasible with sensitivities up to 10−4.•PCR-induced bias could be significantly reduced by the choice of adequate enzymes.•The prevalent transition vs. transversion bias affects site-specific detection limits.•Results from clinical data validated the feasibi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomolecular detection and quantification 2018-05, Vol.15, p.6-12
Hauptverfasser: Stasik, S., Schuster, C., Ortlepp, C., Platzbecker, U., Bornhäuser, M., Schetelig, J., Ehninger, G., Folprecht, G., Thiede, C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 12
container_issue
container_start_page 6
container_title Biomolecular detection and quantification
container_volume 15
creator Stasik, S.
Schuster, C.
Ortlepp, C.
Platzbecker, U.
Bornhäuser, M.
Schetelig, J.
Ehninger, G.
Folprecht, G.
Thiede, C.
description •NGS based detection of low-level SNVs is feasible with sensitivities up to 10−4.•PCR-induced bias could be significantly reduced by the choice of adequate enzymes.•The prevalent transition vs. transversion bias affects site-specific detection limits.•Results from clinical data validated the feasibility of NGS-based MRD detection.•Results help to select suitable biomarkers for MRD quantification. Monitoring of minimal residual disease (MRD) has become an important clinical aspect for early relapse detection during follow-up care after cancer treatment. Still, the sensitive detection of single base pair point mutations via Next-Generation Sequencing (NGS) is hampered mainly due to high substitution error rates. We evaluated the use of NGS for the detection of low-level variants on an Ion Torrent PGM system. As a model case we used the c.1849G > T (p.Val617Phe) mutation of the JAK2-gene. Several reaction parameters (e.g. choice of DNA-polymerase) were evaluated and a comprehensive analysis of substitution errors was performed. Using optimized conditions, we reliably detected JAK2 c.1849G > T VAFs in the range of 0.01–0.0015% which, in combination with results obtained from clinical data, validated the feasibility of NGS-based MRD detection. Particularly, PCR-induced transitions (mainly G > A and C > T) were the major source of error, which could be significantly reduced by the application of proofreading enzymes. The integration of NGS results for several common point mutations in various oncogenes (i.e. IDH1 and 2, c-KIT, DNMT3A, NRAS, KRAS, BRAF) revealed that the prevalent transition vs. transversion bias (3.57:1) has an impact on site-specific detection limits of low-level mutations. These results may help to select suitable markers for MRD detection and to identify individual cut-offs for detection and quantification.
doi_str_mv 10.1016/j.bdq.2017.12.001
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5766748</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2214753517302115</els_id><sourcerecordid>1989592607</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3661-8cb9d3c8b6870f3cc68f045a04d7376637a37c0fb724461d965d8a50df18b0b73</originalsourceid><addsrcrecordid>eNp9kc9rFDEUxwdRbKn9A7xIjl5mzO_MIAilaCsUPbSeQyZ5s80ym0yT7GL715vt1lIvnvIgn_d9yfs0zXuCO4KJ_LTuRnfXUUxUR2iHMXnVHFNKeKsEE69f1EfNac5rXAnBKRPybXNEB8YHzOlxE88CikvxG_8ADhWTVlBq8QN-l_YCAiRTfAzoGu62EKwPK2SWJUVjb9EUE8oQsi9-B8jVPvvIxgnlCs6AwtbOEIt3gHYmeRNKfte8mcyc4fTpPGl-fft6c37ZXv28-H5-dtVaJiVpezsOjtl-lL3CE7NW9hPmwmDuFFNSMmWYsngaFeVcEjdI4XojsJtIP-JRsZPmyyF32Y4bcBZCSWbWS_Ibk-51NF7_exP8rV7FnRY1XfG-Bnx8Ckix_j0XvfHZwjybAHGbNRn6QQxU4v0sckBtijknmJ7HEKz3rvRaV1d670oTqquJ2vPh5fueO_6aqcDnAwB1SzsPSWfrqwJwPtVFaxf9f-L_AIHTpyY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1989592607</pqid></control><display><type>article</type><title>An optimized targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide variants</title><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Stasik, S. ; Schuster, C. ; Ortlepp, C. ; Platzbecker, U. ; Bornhäuser, M. ; Schetelig, J. ; Ehninger, G. ; Folprecht, G. ; Thiede, C.</creator><creatorcontrib>Stasik, S. ; Schuster, C. ; Ortlepp, C. ; Platzbecker, U. ; Bornhäuser, M. ; Schetelig, J. ; Ehninger, G. ; Folprecht, G. ; Thiede, C.</creatorcontrib><description>•NGS based detection of low-level SNVs is feasible with sensitivities up to 10−4.•PCR-induced bias could be significantly reduced by the choice of adequate enzymes.•The prevalent transition vs. transversion bias affects site-specific detection limits.•Results from clinical data validated the feasibility of NGS-based MRD detection.•Results help to select suitable biomarkers for MRD quantification. Monitoring of minimal residual disease (MRD) has become an important clinical aspect for early relapse detection during follow-up care after cancer treatment. Still, the sensitive detection of single base pair point mutations via Next-Generation Sequencing (NGS) is hampered mainly due to high substitution error rates. We evaluated the use of NGS for the detection of low-level variants on an Ion Torrent PGM system. As a model case we used the c.1849G &gt; T (p.Val617Phe) mutation of the JAK2-gene. Several reaction parameters (e.g. choice of DNA-polymerase) were evaluated and a comprehensive analysis of substitution errors was performed. Using optimized conditions, we reliably detected JAK2 c.1849G &gt; T VAFs in the range of 0.01–0.0015% which, in combination with results obtained from clinical data, validated the feasibility of NGS-based MRD detection. Particularly, PCR-induced transitions (mainly G &gt; A and C &gt; T) were the major source of error, which could be significantly reduced by the application of proofreading enzymes. The integration of NGS results for several common point mutations in various oncogenes (i.e. IDH1 and 2, c-KIT, DNMT3A, NRAS, KRAS, BRAF) revealed that the prevalent transition vs. transversion bias (3.57:1) has an impact on site-specific detection limits of low-level mutations. These results may help to select suitable markers for MRD detection and to identify individual cut-offs for detection and quantification.</description><identifier>ISSN: 2214-7535</identifier><identifier>EISSN: 2214-7535</identifier><identifier>DOI: 10.1016/j.bdq.2017.12.001</identifier><identifier>PMID: 29349042</identifier><language>eng</language><publisher>Germany: Elsevier GmbH</publisher><subject>Cancer ; Detection ; Low-level single nucleotide variants ; Minimal residual disease ; Next-Generation sequencing ; Original ; Quantification</subject><ispartof>Biomolecular detection and quantification, 2018-05, Vol.15, p.6-12</ispartof><rights>2017 The Authors</rights><rights>2017 The Authors 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3661-8cb9d3c8b6870f3cc68f045a04d7376637a37c0fb724461d965d8a50df18b0b73</citedby><cites>FETCH-LOGICAL-c3661-8cb9d3c8b6870f3cc68f045a04d7376637a37c0fb724461d965d8a50df18b0b73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5766748/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5766748/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29349042$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stasik, S.</creatorcontrib><creatorcontrib>Schuster, C.</creatorcontrib><creatorcontrib>Ortlepp, C.</creatorcontrib><creatorcontrib>Platzbecker, U.</creatorcontrib><creatorcontrib>Bornhäuser, M.</creatorcontrib><creatorcontrib>Schetelig, J.</creatorcontrib><creatorcontrib>Ehninger, G.</creatorcontrib><creatorcontrib>Folprecht, G.</creatorcontrib><creatorcontrib>Thiede, C.</creatorcontrib><title>An optimized targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide variants</title><title>Biomolecular detection and quantification</title><addtitle>Biomol Detect Quantif</addtitle><description>•NGS based detection of low-level SNVs is feasible with sensitivities up to 10−4.•PCR-induced bias could be significantly reduced by the choice of adequate enzymes.•The prevalent transition vs. transversion bias affects site-specific detection limits.•Results from clinical data validated the feasibility of NGS-based MRD detection.•Results help to select suitable biomarkers for MRD quantification. Monitoring of minimal residual disease (MRD) has become an important clinical aspect for early relapse detection during follow-up care after cancer treatment. Still, the sensitive detection of single base pair point mutations via Next-Generation Sequencing (NGS) is hampered mainly due to high substitution error rates. We evaluated the use of NGS for the detection of low-level variants on an Ion Torrent PGM system. As a model case we used the c.1849G &gt; T (p.Val617Phe) mutation of the JAK2-gene. Several reaction parameters (e.g. choice of DNA-polymerase) were evaluated and a comprehensive analysis of substitution errors was performed. Using optimized conditions, we reliably detected JAK2 c.1849G &gt; T VAFs in the range of 0.01–0.0015% which, in combination with results obtained from clinical data, validated the feasibility of NGS-based MRD detection. Particularly, PCR-induced transitions (mainly G &gt; A and C &gt; T) were the major source of error, which could be significantly reduced by the application of proofreading enzymes. The integration of NGS results for several common point mutations in various oncogenes (i.e. IDH1 and 2, c-KIT, DNMT3A, NRAS, KRAS, BRAF) revealed that the prevalent transition vs. transversion bias (3.57:1) has an impact on site-specific detection limits of low-level mutations. These results may help to select suitable markers for MRD detection and to identify individual cut-offs for detection and quantification.</description><subject>Cancer</subject><subject>Detection</subject><subject>Low-level single nucleotide variants</subject><subject>Minimal residual disease</subject><subject>Next-Generation sequencing</subject><subject>Original</subject><subject>Quantification</subject><issn>2214-7535</issn><issn>2214-7535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kc9rFDEUxwdRbKn9A7xIjl5mzO_MIAilaCsUPbSeQyZ5s80ym0yT7GL715vt1lIvnvIgn_d9yfs0zXuCO4KJ_LTuRnfXUUxUR2iHMXnVHFNKeKsEE69f1EfNac5rXAnBKRPybXNEB8YHzOlxE88CikvxG_8ADhWTVlBq8QN-l_YCAiRTfAzoGu62EKwPK2SWJUVjb9EUE8oQsi9-B8jVPvvIxgnlCs6AwtbOEIt3gHYmeRNKfte8mcyc4fTpPGl-fft6c37ZXv28-H5-dtVaJiVpezsOjtl-lL3CE7NW9hPmwmDuFFNSMmWYsngaFeVcEjdI4XojsJtIP-JRsZPmyyF32Y4bcBZCSWbWS_Ibk-51NF7_exP8rV7FnRY1XfG-Bnx8Ckix_j0XvfHZwjybAHGbNRn6QQxU4v0sckBtijknmJ7HEKz3rvRaV1d670oTqquJ2vPh5fueO_6aqcDnAwB1SzsPSWfrqwJwPtVFaxf9f-L_AIHTpyY</recordid><startdate>20180501</startdate><enddate>20180501</enddate><creator>Stasik, S.</creator><creator>Schuster, C.</creator><creator>Ortlepp, C.</creator><creator>Platzbecker, U.</creator><creator>Bornhäuser, M.</creator><creator>Schetelig, J.</creator><creator>Ehninger, G.</creator><creator>Folprecht, G.</creator><creator>Thiede, C.</creator><general>Elsevier GmbH</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180501</creationdate><title>An optimized targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide variants</title><author>Stasik, S. ; Schuster, C. ; Ortlepp, C. ; Platzbecker, U. ; Bornhäuser, M. ; Schetelig, J. ; Ehninger, G. ; Folprecht, G. ; Thiede, C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3661-8cb9d3c8b6870f3cc68f045a04d7376637a37c0fb724461d965d8a50df18b0b73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Cancer</topic><topic>Detection</topic><topic>Low-level single nucleotide variants</topic><topic>Minimal residual disease</topic><topic>Next-Generation sequencing</topic><topic>Original</topic><topic>Quantification</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stasik, S.</creatorcontrib><creatorcontrib>Schuster, C.</creatorcontrib><creatorcontrib>Ortlepp, C.</creatorcontrib><creatorcontrib>Platzbecker, U.</creatorcontrib><creatorcontrib>Bornhäuser, M.</creatorcontrib><creatorcontrib>Schetelig, J.</creatorcontrib><creatorcontrib>Ehninger, G.</creatorcontrib><creatorcontrib>Folprecht, G.</creatorcontrib><creatorcontrib>Thiede, C.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Biomolecular detection and quantification</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stasik, S.</au><au>Schuster, C.</au><au>Ortlepp, C.</au><au>Platzbecker, U.</au><au>Bornhäuser, M.</au><au>Schetelig, J.</au><au>Ehninger, G.</au><au>Folprecht, G.</au><au>Thiede, C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An optimized targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide variants</atitle><jtitle>Biomolecular detection and quantification</jtitle><addtitle>Biomol Detect Quantif</addtitle><date>2018-05-01</date><risdate>2018</risdate><volume>15</volume><spage>6</spage><epage>12</epage><pages>6-12</pages><issn>2214-7535</issn><eissn>2214-7535</eissn><abstract>•NGS based detection of low-level SNVs is feasible with sensitivities up to 10−4.•PCR-induced bias could be significantly reduced by the choice of adequate enzymes.•The prevalent transition vs. transversion bias affects site-specific detection limits.•Results from clinical data validated the feasibility of NGS-based MRD detection.•Results help to select suitable biomarkers for MRD quantification. Monitoring of minimal residual disease (MRD) has become an important clinical aspect for early relapse detection during follow-up care after cancer treatment. Still, the sensitive detection of single base pair point mutations via Next-Generation Sequencing (NGS) is hampered mainly due to high substitution error rates. We evaluated the use of NGS for the detection of low-level variants on an Ion Torrent PGM system. As a model case we used the c.1849G &gt; T (p.Val617Phe) mutation of the JAK2-gene. Several reaction parameters (e.g. choice of DNA-polymerase) were evaluated and a comprehensive analysis of substitution errors was performed. Using optimized conditions, we reliably detected JAK2 c.1849G &gt; T VAFs in the range of 0.01–0.0015% which, in combination with results obtained from clinical data, validated the feasibility of NGS-based MRD detection. Particularly, PCR-induced transitions (mainly G &gt; A and C &gt; T) were the major source of error, which could be significantly reduced by the application of proofreading enzymes. The integration of NGS results for several common point mutations in various oncogenes (i.e. IDH1 and 2, c-KIT, DNMT3A, NRAS, KRAS, BRAF) revealed that the prevalent transition vs. transversion bias (3.57:1) has an impact on site-specific detection limits of low-level mutations. These results may help to select suitable markers for MRD detection and to identify individual cut-offs for detection and quantification.</abstract><cop>Germany</cop><pub>Elsevier GmbH</pub><pmid>29349042</pmid><doi>10.1016/j.bdq.2017.12.001</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2214-7535
ispartof Biomolecular detection and quantification, 2018-05, Vol.15, p.6-12
issn 2214-7535
2214-7535
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5766748
source PubMed Central; Alma/SFX Local Collection; EZB Electronic Journals Library
subjects Cancer
Detection
Low-level single nucleotide variants
Minimal residual disease
Next-Generation sequencing
Original
Quantification
title An optimized targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide variants
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T20%3A08%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20optimized%20targeted%20Next-Generation%20Sequencing%20approach%20for%20sensitive%20detection%20of%20single%20nucleotide%20variants&rft.jtitle=Biomolecular%20detection%20and%20quantification&rft.au=Stasik,%20S.&rft.date=2018-05-01&rft.volume=15&rft.spage=6&rft.epage=12&rft.pages=6-12&rft.issn=2214-7535&rft.eissn=2214-7535&rft_id=info:doi/10.1016/j.bdq.2017.12.001&rft_dat=%3Cproquest_pubme%3E1989592607%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1989592607&rft_id=info:pmid/29349042&rft_els_id=S2214753517302115&rfr_iscdi=true